Dataset from A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00010186
下载链接
链接失效反馈官方服务：
资源简介：
This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily
dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with
either transthyretin genetic variants or wild-type transthyretin resulting in amyloid
cardiomyopathy.
创建时间：
2025-10-13
